Romualdi Patrizia, Candeletti Sanzio
Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Bologna, Italy -
Minerva Med. 2016 Apr;107(2):114-22.
The management of cancer pain presents manifold challenges: even though background pain is adequately controlled, patients frequently experience episodes of acute pain exacerbation known as breakthrough cancer pain (BTcP). The characteristics of BTcP are a rapid onset, a short duration, and a severe intensity. An innovative sublingual fentanyl citrate formulation (Vellofent®) has been developed to target BTcP. The new formulation allows to increase the solubility of fentanyl and to provide optimal oromucosal conditions for rapid drug absorption, thus featuring a shorter time to onset of pain relief (from 6 minutes post-administration).
尽管背景疼痛得到了充分控制，但患者仍经常经历被称为突破性癌症疼痛（BTcP）的急性疼痛加剧发作。BTcP的特点是起病迅速、持续时间短且强度剧烈。一种创新的枸橼酸芬太尼舌下制剂（Vellofent®）已被开发用于治疗BTcP。这种新制剂能够提高芬太尼的溶解度，并为药物快速吸收提供最佳的口腔黏膜条件，因此具有更短的起效时间（给药后6分钟开始起效）。
